Stifel Downgrades CymaBay Therapeutic (CBAY) to Hold
Tweet Send to a Friend
Stifel analyst Derek Archila downgraded CymaBay Therapeutic (NASDAQ: CBAY) from Buy to Hold with a price target of $4.00 (from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE